- Daily low-dose aspirin taken for an average of seven years did not affect the risk of dementia in adults with type 2 diabetes.
- The aspirin regimen was neither protective nor harmful regarding dementia risk.
- A heart attack or stroke was associated with at least double the risk of dementia.
Embargoed until 10 a.m. CT/11 a.m. ET, Monday, Nov. 15, 2021
DALLAS, Nov. 15, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline among adults with type 2 diabetes, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2021. The meeting is fully virtual, Saturday, November 13-Monday, November 15, 2021, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.
While daily low-dose aspirin may be prescribed to reduce the risk of having a second heart attack or clot-related stroke, it is also associated with internal bleeding including brain bleeds. “The overall effect of aspirin on dementia and cognitive impairment was uncertain,” said study author, Jane Armitage, F.R.C.P., a professor of clinical trials and epidemiology at the Nuffield Department of Population Health at the University of Oxford in the U.K. “Aspirin may be protective for dementia by preventing some strokes due to blockages, or it may increase the risk because of bleeding into the brain.”
According to the American College of Cardiology/American Heart Association 2019 primary prevention recommendations, adults without known cardiovascular disease should only take aspirin for heart attack and stroke prevention if they have the highest risk of cardiovascular disease and a very low risk of bleeding. Recent draft guidance from the U.S. Preventive Services Task Force agrees with this approach – daily low-dose aspirin should not be prescribed for cardiovascular disease prevention in adults who do not have existing cardiovascular disease. However, adults with previously diagnosed cardiovascular disease or a previous cardiac event such as a heart attack or stroke, should continue to take daily low-dose aspirin if prescribed by their physician.
Researchers aimed to assess the effects of low-dose aspirin on the risk of dementia and cognitive impairment in participants enrolled in the ASCEND (A Study of Cardiovascular Events in Diabetes) trial. The ASCEND trial included more than 15,000 adults with type 2 diabetes living in the U.K. who had not experienced a stroke, heart attack or other circulatory issue, and who did not have dementia at the beginning of the study. Half of the participants took a single 100-milligram aspirin, and half received an identical placebo pill daily. The study tracked participants for nearly nine years, with an average of about seven years of treatment and almost two additional years of follow up.
At the end of follow-up, presence of dementia was determined by several methods: results of a cognitive function test (Telephone Interview of Cognitive Status and verbal fluency or the Healthy Minds test); diagnoses listed in hospital admission data or death records; and other indicators of cognitive impairment listed in electronic health records. Researchers also noted the occurrence of serious illness, heart attacks, strokes or major internal bleeding.
Researchers found 1,146 participants experienced “broad dementia,” meaning dementia, cognitive impairment or delirium or confusion; and they were prescribed dementia medications or received a referral to a memory clinic or geriatric psychiatry.
“The results show no clear effect of daily low-dose aspirin on the risk of dementia, with a non-significant 9% proportional reduction in risk. However, the uncertainty around this 9% benefit ranged from a 19% reduction in dementia risk to a 2% increase. This is reassuring that an increase in the risk of dementia is unlikely for the millions of people worldwide who regularly take aspirin to protect against the risk of heart attack and stroke,” said Armitage. “The results mean a modest benefit of daily low-dose aspirin on risk of dementia is possible, however, we need studies with more people developing dementia to be sure.”
The researchers did find, however, that serious vascular events, such as a heart attack or major bleeding episodes like a stroke, were associated with dementia. There were 990 participants who survived a major vascular event and 496 who survived a major bleed during the study.
- Study participants who experienced a major vascular event were almost two and a half times more likely to experience dementia, memory loss, confusion or mental decline during the study compared to the participants who did not have a major vascular event.
- Those who had a major bleed were twice as likely to experience dementia, memory loss, confusion or mental decline than those who did not have a bleed.
A limitation of the study is there may not be enough cases of reported dementia to make a clear assessment of the effect of daily low-dose aspirin on the risk of dementia. “A larger study with more cases of dementia may be able to detect any benefits or harms. We plan to continue to follow the trial participants for several more years to see if more cases of dementia emerge,” Armitage said.
Co-authors are Louise Bowman, M.D.; Marion Mafham, M.D.; and Sarah Parish, D.Phil. Authors’ disclosures are listed in the abstract.
The study was funded by Alzheimer’s Research UK, Bayer, the British Heart Foundation and the UK Medical Research Council.
- Multimedia is available on the right column of the release link https://newsroom.heart.org/news/long-term-low-dose-aspirin-did-not-affect-risk-of-dementia-in-adults-with-type-2-diabetes?preview=13ca0109a06b471e83384d695662fa6d
- AHA Scientific Sessions 2021 Online Program Planner
- Many Americans With Dementia Don’t Know They Have It Study
- FAQs about Brain Health
- For more news at AHA Scientific Sessions 2021, follow us on Twitter @HeartNews #AHA21
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
The American Heart Association’s Scientific Sessions 2021 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care professionals worldwide. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates in a fully virtual experience Saturday, November 13 through Monday, November 15, 2021. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2021 on social media via #AHA21.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective:
AHA Communications & Media Relations in Dallas: 214-706-1173; email@example.com
Maggie Francis: 214-706-1382; firstname.lastname@example.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)